



## **Expansion of GHG's BioPharma Division**

Global Hemp Group is creating a blueprint, not only for now, but for the next 5 years, to deliver a long term strategy that drives consistency and sustainable success

# Disclaimers & Cautionary Statements

**TERMS OF USE AND DISCLAIMER** - This Corporate Brochure is provided to you as an Accredited Investor or as a close friend or business associate of one of the directors, or management team of Global Hemp Group Inc. This is not an invitation to the public to subscribe for securities and the foregoing has not been reviewed nor approved by any Securities Commission or Stock Exchange. This document may not be forwarded to other parties.

Certain of the information contained in this presentation may contain "forward-looking information". Forward-looking information and Statements may include, among others, statements regarding the future plans, costs, objectives or performance of the Company, or the assumptions underlying any of the foregoing. In this presentation, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. These risks, uncertainties and assumptions include, but are not limited to, those described under "Risk Factors" in the Company's Management Discussion and Analysis relating to the Company's financial statements, available on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) and could cause actual events or results to differ materially from those projected in any forward-looking statements. The Company does not intend, nor does the Company undertake any obligation, to update or revise any forward-looking information or statements contained in this presentation to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws. This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person (as defined in Regulation S under the United States Securities Act of 1933, as amended, or in any other jurisdiction in which such an offer would be illegal. Global Hemp Group shares have not been and will not be registered under the Securities Act.

# Global Hemp Group

Global Hemp Group (“GHG”) is a Canadian publicly traded company focused on two business segments:

**Biopharma:** The Health and Wellness Division is acquiring exclusive licensing of patents and other IP. To date the Company has executed agreements with Serres Thériault (2021) Inc., B-Organic R&D Corp. and Apollon Formularies plc.

**SERRES  
THÉRIAULT  
(2021) INC.**



**Industrial Hemp:** This division is focused on, but not limited to, the carbon negative use of hemp-based construction materials and carbon neutral bio-energy sources.



# Expansion of BioPharma Division

- Global Hemp Group has been operating across the industrial hemp industry since 2014, including the cultivation of hemp for CBD extraction in both Canada and the U.S. Earlier in 2023, the Company had the opportunity to expand its cannabinoid segment of the business with the acquisition of exclusive licensing of Apollon Formularies patents and IP (*see page 7 for more info*), and creating a BioPharma Division. This business segment was further expanded with the execution of the LOI with B-Organic R&D Corp. for the exclusive licensing of their Bioactive Lipid Agents technology for bioavailability enhancement (*see page 5 & 6*), and the Exclusive Option Agreement with Serres Thériault (2021) Inc. a multi-faceted vertically integrated cannabis operator in News Brunswick (*see page 8*).
- With these exclusive licenses in place and having direct application in the CBD and medicinal cannabis space, GHG will be able to add this innovative patented technology to its product portfolio, solving the issue of bioavailability, which is a global problem when it comes to existing and developing medications.
- With the addition of new team members that have experience in operating across both the CBD and medicinal cannabis space, will allow for a more heightened focus globally on who we are and what we do.

# Bioavailability

## Problem

- ***Bioavailability is key to the amount of dosage that is administered to the body***
- On average 40% of currently marketed medications and 70% of new medications in development have a poor aqueous solubility. This makes medications hard to formulate.
- The prerequisite for good absorption through an oral delivery method is ensuring that the Active Pharma Ingredient (API) is soluble in the gastrointestinal (GI) media and releasing a sufficient amount of active pharmaceutical agent at the site of absorption.
- *What cannot be dissolved, cannot be absorbed, so cannot treat.*



## Solution

- **B-Organic R&D Corp. has created its Bioactive Lipid Agents (“BLA”) technology, a patented innovative matrix which is able to increase the solubility and bioavailability of numerous “poorly soluble pharma ingredients” including cannabinoids.**
- The application of BLA extends to numerous industries such as food, pharmaceuticals, healthcare, drugs, agriculture, and nutraceuticals.
- **GHG has executed an LOI with B-Organic to exclusively license its BLA technology,** which is the next step in the Company's strategic expansion of its biopharma business segment
- GHG is now working with its manufacturers to enhance existing products utilizing the BLA technology as well looking to begin developing new products that can be patented and distributed where legally permitted

# BLA Technology - Research showed the following can be achieved with cannabinoids:

- Conversion of cannabinoids into solid powders permitting to broaden the application field under different dosage forms: tablets, capsules, patch for pharmaceutical application or for recreational use as powders (ready to use) in sugar sachet form, easily added to food, drinks, energy drinks, baking goods, dairy products, etc.



- 100 % Generally Recognized As Safe (“GRAS”)
- Excipient FDA Cleared
- Increase the bioavailability of the cannabinoids (and its analogues): *less active ingredient is required* in order to target the same dosage or effect, thus resulting in a decrease in cost and improve the safety
- Accurate dosing for immediate or controlled release of the cannabinoids or its derivatives
- Reduced side effects
- Conversion process requires **no chemicals, no solvents**, and no heat
- Cannabinoid odor can be reduced if desired
- Costs are low and product is simple to manufacture



# Apollon Formularies Exclusive License

GHG acquired the exclusive perpetual license for North America (the United States, Canada and Mexico) to Apollon's Intellectual Property and proprietary technology, including, but not limited to, four key patents along with any and all associated preclinical and clinical data relating to the patents and proprietary technology. The Exclusive Licensing was expanded for the two Composition patents below to include Israel and the European Union with extension to Morocco.

- Compositions and Methods for Treatment of Cancers
- Compositions and Methods for Treatment of Inflammation
- Methods for Treatment of Human Cancers Using Cannabis Compositions
- Methods for Treatment of Human Cancers Using Mushroom Compositions
- BIOENSIS Preclinical Data reflecting independent 3D cell culture testing of cannabis and mushroom formulations included in the patent applications



In addition to the above formulations, GHG is working with Apollon and the Company's manufacturer to produce a line of CBD and functional mushrooms that will be marketed by the Company's non-exclusive licensee – Medicinal One LLC.

Product formulations focus on: Sleep / Inflammation & Pain / Performance / Neurological "Nootropic"

# Exclusive Option Agreement - STI



**January 2024 GHG executed an Exclusive Option Agreement to acquire Serres Thériault (2021) Inc. (“STI”), a multi-faceted vertically integrated cannabis operator in News Brunswick.**

- This transaction provides the Company a clear pathway to further diversify GHG’s activities in the industry and importantly, access to licenses from Health Canada. This will be an important step in furthering the expansion of the Company’s Health and Wellness division, which initial foundation encompasses the Exclusive Licenses relating to key patents and IP acquired from Apollon Formularies plc in 2023.
- The facility is currently licensed for Cannabis Micro Processing, a Farmgate Retail Store and Research & Development.
- The acquisition includes an 8.6-acre compound and its five buildings for production and sales, along with property, 6,000 sq ft of greenhouse, equipment, inventory, genetics, Intellectual Property, an onsite retail location, and one offsite retail location.
- [For Further Information on the Option Agreement \(click to view\)](#)

## Retail Outlets

- STI’s offsite retail store located in St. Quentin, New Brunswick, opened its doors to the public in November 2023. ***This is one of only eight exclusive private retail outlets located in the province of NB.*** STI advises that sales at this retail location have exceeded expectations to date and has already reached profitability.
- Pinnacle Farms, a second retail operation located onsite is slated to open in April 2024. This store will be licensed as a Farmgate retail model operation in NB with exclusive distribution of products manufactured by STI.



# Business Model



With the recent appointment of Ramsey Douglas to GHG's Board of Directors, the Company has begun to build its marketing team for products that will be manufactured through outsourcing under various licenses. Prior to joining GHG, over the last 12 months he has been building a global business model that he has brought to GHG. This will allow the Company to hit the ground running in terms of product development and sales.

With medicinal cannabinoids being the key focus, Ramsey have developed a network of manufacturing and distribution partners globally that is expected to create a pipeline of business for 2024 onwards. This includes access into the United Kingdom, Guernsey, Germany, Austria, The Nordics, South Africa, Australia, New Zealand and LATAM.

Global Hemp has a unique opportunity with the licensing of the BLA increased bioavailability technology. This will not only be used in any products developed as a group, but there is also the opportunity to sell the raw material to third parties across the CBD and Medicinal Cannabis space globally. This in itself is a game changer because as a brand you want a product with the most efficacy and as a manufacturer you want to be able to offer the highest quality of product. By making a product much more effective, it is a win-win for everyone. It also means that as a manufacturer, manufacturing costs are lower as you will use less raw material to get a much better effect.

# The Role of GHG BioPharma


To get the correct messages in front of the correct audiences, you either need a huge sales force, or an effective marketing team that understand the industry, and through existing global relationships are able to deliver relevant content globally, to the correct markets.

With global distribution partners in place who will look after the sales side of the business, the GHG team will focus heavily on marketing, not only around the brand, but through doctors, pharmacists and the end user, which are all of our target markets.

By educating the people that prescribe and dispense, this makes our role a lot easier, as these are the people that can implement change and mindset across the practices where they operate. To make sure that we are conveying the correct messaging, the education program will be put in place with the help of our distribution partners who already operate in there respective markets. By understanding our partners pain points when speaking with doctors and pharmacists alike, we can tailor the program to what it needs to be. With similar issues globally, with tweaks by Country we will have a program which can be rolled out globally.

# BioPharma Partners

1. United Kingdom (3)
2. Guernsey
3. Germany
4. Austria
5. Nordics
6. United States
7. Mexico
8. Columbia
9. LATAM
10. South Africa
11. Australia
12. New Zealand




## Global Footprint of Distribution Partner Relationships

# Global Marketing/Branding



*Existing Relationships of the marketing team that can be utilized going forward.*

# GHG BioPharma Team



*How the Company looks to build out the team as additional funding becomes available.*

# GHG's Board of Directors/Officers

**Curt Huber**



**Interim President & CEO** – 35+ years experience in all facets of public companies

**Ramsey Douglas**



Sales and marketing strategist. Has been in the CBD industry since 2017

**Aurelio Useche**



**CMA, CPA, MBA**  
Over 20 years of senior management experience

**Yousef Kamhiyah**



**CPA, CBV**  
15 years experience in accounting, business valuation, tax, and business strategy.

# GHG's Advisory Board

**Nikolas Perrault**  
Special Advisor  
Capital Markets



**CFA** – CEO Twilight Capital, a capital market advisory consulting firm

**Louis René Vallée**  
Business  
Dev Advisor



Marketing specialist and expert in brand creation, new product intros & positioning

**Víctor M. Castaño**  
Head of GHG's  
R&D Division



**Ph.D.** - Prof. Castaño is a recognized int'l leader in several areas of applied science & technology

**Mathieu Couillard**  
Bus Dev & Capital  
Markets Advisor



**B.Sc.** - An experienced investment banker with extensive experience in the cannabis space

**Paul Perrault**  
Industrial Hemp  
Advisor



**M.A., Ph.D.**  
An economist trained in Rural Development. Involved in the hemp industry since 2014

*GHG is currently looking to expand its Advisory Board with individuals to assist in the expansion of its BioPharma Division*

# For Further Information Contact

Investor Relations

778-726-2900

[info@globalhempgroup.com](mailto:info@globalhempgroup.com)

## Capital Structure

Jan 31, 2024

**Shares Issued & Outstanding**      **24,291,458**

Warrants      5,530,000

Options      775,000

## Trading Symbols

CSE: GHG / OTCPK: GBHPF /

FRANKFURT: GHG0

## Recent News Announcements

Feb 21, 2024 - [GHG Welcomes Louis Rene Vallee as Business Development Advisor](#)

Feb 14, 2024 - [GHG Provides Update on its Industrial Hemp Division](#)

Jan 31, 2024 - [GHG Announces Closing of Debt Settlement](#)

Jan 15, 2024 - [GHG Announces Execution of Option Agreement to Acquire Serres Thériault \(2021\) Inc.](#)

Oct 11, 2023 - [GHG Executes LOI with B-Organic R&D Corp. to Create 50% JV Around its Patented Bioactive Lipid Agents Technology](#)

Oct 3, 2023 - [GHG Announces Ramsey Douglas Appointed to the Board of Directors](#)